Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a...
Among patients with high-risk, HER2-negative early breast cancer and germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic or likely pathogenic variants, adjuvant olaparib after comp...